Join        Login             Stock Quote

Allergan (AGN) To Buy Skin Care Business Of Skinmedica For $350M

 November 16, 2012 12:47 PM

(By Balaseshan) Allergan Inc. (NYSE: AGN), a multi-specialty health care company, said it has agreed to buy topical aesthetics skin care business of privately-held SkinMedica Inc. for $350 million up-front.

The acquisition does not include the SkinMedica Colorescience aesthetic make-up line. SkinMedica will be spinning out the Colorescience business in connection with the closing of the acquisition.

The business includes a variety of "physician dispensed" non-prescription aesthetic skin care products and prescription products. Allergan will also pay SkinMedica an additional $25 million contingent upon the acquired products achieving a specific level of net sales.

[Related -Allergan, Inc. (NYSE:AGN): Is Ozurdex A Potential Sleeper Hit?]

Following the acquisition, Allergan plans to operate SkinMedica as a separate global business and will leverage a number of Allergan's existing preferred customer programs with the SkinMedica product line to provide additional benefits to physicians and patients.

"The acquisition of SkinMedica will nicely complement our existing facial aesthetics business, which includes products such as Botox Cosmetic, Juvederm, and Latisse, and will enable us to take a leadership position in the growing 'physician dispensed' topical aesthetics skin care category," said David Pyott, Chief Executive of Allergan.

Bob Rhatigan, who currently serves as Senior Vice President - Facial Aesthetics of Allergan, will assume the role of Senior Vice President, General Manager and Chief Executive, SkinMedica.

[Related -Bond Yields Rise On Stronger Economic Data]

Mary Fisher, current Chief Executive of SkinMedica, will join Allergan and assist Rhatigan in the acquisition integration to ensure the maximization of revenue building opportunities.

The Allergan topical aesthetics sales force and the SkinMedica sales force will continue to represent their respective product lines over the near term.

Following the completion of the acquisition, a larger and combined SkinMedica sales force will assume responsibility for the line of products including the revolutionary SkinMedica TNS product line, Allergan's Vivité product line and Latisse, the one and only FDA approved product to treat inadequate or not enough eye lashes.

The acquisition of SkinMedica's topical aesthetics skin care business is expected to close later this year.

AGN is trading up 0.94% at $88.78 on Friday. The stock has been trading between $78.42 and $97.09 for the past 52 weeks.

iOnTheMarket Premium


11/19/2012 12:11:33 AM
Revitol skin care by Natalie
The new above pertaining to the acquiring the skincare above is really a nice deal and I can assume a worthy benefit for them out of it
Rating: (1) (0)
Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageTwo Picks to Play Defense in a Slowing Economy

Is the economy slowing? Last Thursday the Institute for Supply Management (ISM) reported that its read on...

article imageUS Jobless Claims Fall, Moving Closer To Multi-Decade Low… Again

US jobless claims continue to cast a positive glow on the outlook for the labor market. Today’s weekly read on...

article imageLong-term Relationships and Credit Scores

Unlike many commentators, I tend to think credit scores are a good read on...

article imageIn Defense Of Rolling Return Charts

Robeco’s Lukas Daalder has a bit of an issue with rolling-performance graphics. Bashing a recent chart of read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.